Serotype distribution ofStreptococcus pneumoniain children with invasive disease in Turkey: 2015-2018

Basit Öğe Kaydı
dc.contributor.authorCeyhan, Mehmet
dc.contributor.authorAykac, Kubra
dc.contributor.authorGurler, Nezahat
dc.contributor.authorOzsurekci, Yasemin
dc.contributor.authorOksuz, Lutfiye
dc.contributor.authorAltay Akisoglu, Ozlem
dc.contributor.authorBirinci, Asuman
dc.date.accessioned2020-12-01T12:01:01Z
dc.date.available2020-12-01T12:01:01Z
dc.date.issued2020
dc.departmentEge Üniversitesien_US
dc.description.abstractObjectives To determine the serotype distribution of pneumococcus causing invasive pneumococcal disease (meningitidis, bacteremia and empyema) in children in Turkey, and to observe potential changes in this distribution in time to guide effective vaccine strategies. Methods We surveyedS. pneumoniaewith conventional bacteriological techniques and with real-time polymerase chain reaction (RT-PCR) in samples of cerebrospinal fluid (CSF), blood and pleural fluid.S. pneumoniaestrains were isolated from 33 different hospitals in Turkey, which are giving health services to approximately 60% of the Turkish population. Results A total of 167 cases were diagnosed with invasive pneumococcal disease between 2015 and 2018. We diagnosed 52 (31.1%) patients with meningitis, 104 (62.2%) patients with bacteremia, and 11 (6.6%) patients with empyema. Thirty-three percent of them were less than 2 years old and 56% less than 5 years old. Overall PCV13 serotypes accounted for 56.2% (94/167). the most common serotypes were 19 F (11.9%), 1 (10.7%) and 3 (10.1%). Conclusions Besides the increasing frequency of non-vaccine serotypes, vaccine serotypes continue to be a problem for Turkey despite routine and high-rate vaccination with PCV13 and significant reduction reported for the incidence of IPD in young children. Since new candidate pneumococcal conjugate vaccines with more serotype antigens are being developed, continuing IPD surveillance is a significant source of information for decision-making processes on pneumococcal vaccination.en_US
dc.description.sponsorshipPfizerPfizeren_US
dc.description.sponsorshipThe study was supported by Pfizer.en_US
dc.identifier.doi10.1080/21645515.2020.1747931en_US
dc.identifier.issn2164-5515
dc.identifier.issn2164-554X
dc.identifier.pmid32530357en_US
dc.identifier.scopus2-s2.0-85087117054en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1080/21645515.2020.1747931
dc.identifier.urihttps://hdl.handle.net/11454/62248
dc.identifier.wosWOS:000545468700001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofHuman Vaccines & Immunotherapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEpidemiologyen_US
dc.subjectserotypesen_US
dc.subjectstreptococcus pneumoniaen_US
dc.subjectsurveillanceen_US
dc.subjectTurkeyen_US
dc.titleSerotype distribution ofStreptococcus pneumoniain children with invasive disease in Turkey: 2015-2018en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu